NCT06763926 Intranasal Nafarelin For Triggering Oocyte Maturation
| NCT ID | NCT06763926 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Fundacion Dexeus |
| Condition | Fertility Preservation |
| Study Type | INTERVENTIONAL |
| Enrollment | 154 participants |
| Start Date | 2026-10-14 |
| Primary Completion | 2028-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 154 participants in total. It began in 2026-10-14 with a primary completion date of 2028-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.
Eligibility Criteria
Inclusion Criteria: * Women undergoing fertility preservation cycles with oocyte cryopreservation * Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s) * BMI 18 - 30 kg/m2 Exclusion Criteria: * Allergy or hypersensitivity to either of the study drugs * Hypopituitarism * Known pituitary tumour * Contraindication to intranasal medication administration * Previous poor response to agonist trigger
Contact & Investigator
Nikolaos P Polyzos, MD, PhD
PRINCIPAL INVESTIGATOR
Dexeus Fertility
Frequently Asked Questions
Who can join the NCT06763926 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 40 Years, studying Fertility Preservation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06763926 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06763926 currently recruiting?
Yes, NCT06763926 is actively recruiting participants. Contact the research team at nikpol@dexeus.com for enrollment information.
Where is the NCT06763926 trial being conducted?
This trial is being conducted at Sabadell, Spain, Sant Cugat del Vallès, Spain, Reus, Spain, Barcelona, Spain and 1 additional location.
Who is sponsoring the NCT06763926 clinical trial?
NCT06763926 is sponsored by Fundacion Dexeus. The principal investigator is Nikolaos P Polyzos, MD, PhD at Dexeus Fertility. The trial plans to enroll 154 participants.